Grifols delivered 7.4% constant currency revenue growth to €1.02bn, with an 11ppt forex headwind (primarily due to a depreciating USD) reducing the reported number to a decline of 3.6%. NB All revenue growth numbers at cc, unless specified otherwise. The core bioscience’s (79% of revenue) growth momentum slowdown from 11.9% (Q1 17) to 5.8%, more in line with the sector growth, to €808m, was primarily impacted by a decline in Factor VIII, while the other protein-types maintaine
17 May 2018
No surprises in Q1...work still in progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
No surprises in Q1...work still in progress
Grifols, S.A. Class A (GRF:WBO) | 0 0 1.0% | Mkt Cap: 14,874m
- Published:
17 May 2018 -
Author:
Kamla Singh -
Pages:
3
Grifols delivered 7.4% constant currency revenue growth to €1.02bn, with an 11ppt forex headwind (primarily due to a depreciating USD) reducing the reported number to a decline of 3.6%. NB All revenue growth numbers at cc, unless specified otherwise. The core bioscience’s (79% of revenue) growth momentum slowdown from 11.9% (Q1 17) to 5.8%, more in line with the sector growth, to €808m, was primarily impacted by a decline in Factor VIII, while the other protein-types maintaine